Backes, Floor J <br/><br/>
Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian cancer?  [electronic resource] 

 -  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society  Jun 2013 
 - 833-8 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1525-1438 
<br/><br/><label>Standard No.: </label>10.1097/IGC.0b013e318290ea69  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Bevacizumab<br/>Carboplatin--administration & dosage<br/>Cisplatin--administration & dosage<br/>Cyclophosphamide--administration & dosage<br/>Disease Progression<br/>Docetaxel<br/>Drug Resistance, Neoplasm--drug effects<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Middle Aged<br/>Neoplasm Recurrence, Local--drug therapy<br/>Neoplasm Staging<br/>Ovarian Neoplasms--drug therapy<br/>Paclitaxel--administration & dosage<br/>Prognosis<br/>Retrospective Studies<br/>Survival Rate<br/>Taxoids--administration & dosage<br/>Topotecan--administration & dosage